<DOC>
	<DOCNO>NCT00904644</DOCNO>
	<brief_summary>Since June 2007 , raltegravir available Switzerland within name patient program patient virologic failure , triple class experience resistance , treatment option . This proposal design evaluate efficacy safety data among patient receive raltegravir within routine clinical practice Switzerland participate Swiss HIV Cohort Study . This combined retrospective analysis patient already receive raltegravir prospective part patient enter name patient program follow standardized way . In prospective part , patient also able receive raltegravir case intolerance current medication virologic suppression . The analysis primarily use descriptive statistic . In addition , assess duration virologic response focus predictor HIV RNA suppression follow-up least 6 month . In prospective part , assess trough plasma level raltegravir antiretrovirals . In patient develop virologic failure , genotypic phenotypic resistance raltegravir ( antiretrovirals ) perform characterize evolution resistance raltegravir-containing regimen .</brief_summary>
	<brief_title>Raltegravir Swiss HIV Cohort Study</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>patient treat Raltegravir within Swiss HIV Cohort Study drop Swiss HIV Cohort study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral treatment</keyword>
	<keyword>Swiss HIV Cohort Study</keyword>
	<keyword>drug resistance</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>Treatment</keyword>
</DOC>